As a leading CGM maker, DexCom is likely to play a significant role in diabetes care for years, possibly decades. Given all ...

DexCom's revised FY24 sales guidance in the Q2 earnings call led to a $18bn valuation reset. Read why I think DXCM stock is a ...

Wells Fargo analyst Larry Biegelsen maintained a Buy rating on Dexcom (DXCM – Research Report) yesterday and set a price target of ...

Stock analysis is all about predictions – but as wits from Mark Twain to Yogi Berra have reminded us, predictions are hard, ...

DexCom stock has fallen 41% this year ... "They are working on two products: one is a shot that you would take once a month, and the other is a pill, which is the holy grail and early studies ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Continuous glucose monitors are already multi-billion dollar products due to demand from ... Each biosensor can be worn for up to two weeks. Dexcom's Stelo is available at a price of up to $ ...

Going forward, Dexcom’s plan is to bring its promising technology to ... launching several campaigns focused on its CGM products, including its name, image, likeness (NIL) program for college athletes ...

The more patients within DexCom's installed base of CGM customers, the more attractive it is for other companies to make their diabetes-centered products and services compatible with DexCom's.

Shelomi Sanders, the daughter of Colorado Football head coach Deion Sanders, goes in-depth with Natalie Esquire and ...

Stelo was launched this year and could be an underrated growth catalyst. It could make DexCom's products accessible to a broader market, and thus significantly expand the company's prospects ...